A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma

Archives of Ophthalmology
A AlmJacquie McDermott

Abstract

To evaluate the 5-year safety and efficacy of adjunctive 0.005% latanoprost once daily. Patients with primary open-angle or exfoliation glaucoma who completed a 3-year, open-label, uncontrolled, prospective trial could enter a 2-year extension phase. High-resolution color photographs of irides were taken at baseline and at 14 subsequent visits. Photographs were assessed for change in iris pigmentation compared with baseline. Intraocular pressures and adverse events were recorded. Development and progression of increased iris pigmentation over 5 years. Of the 519 original patients, 380 enrolled in the extension phase with approximately 89% having an eye color known to be susceptible to color change. After 5 years, most patients had no increase in iris pigmentation, but certain colored irides exhibited notably greater susceptibility than others. For those whose irides did change, onset occurred during the first 8 months in 74% and during the first 24 months in 94%. No patient developed an increase in pigmentation after month 36; the rate of progression decreased over time. Adverse event profiles were similar for patients with and without increased pigmentation. The overall mean intraocular pressure reduction from baseline of 25% ...Continue Reading

Associated Clinical Trials

Citations

Mar 25, 2008·Therapeutics and Clinical Risk Management·Robert J Noecker
Aug 30, 2008·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Habib Ur Rehman
Sep 7, 2007·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Andrew SuttonAuli Ropo
Mar 29, 2008·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Bernard SchwartzJeff Martin
Oct 28, 2009·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Mei TsudaMiyo Matsumura
Dec 5, 2012·Japanese Journal of Ophthalmology·Takaiko YoshinoHaruki Abe
Dec 21, 2004·Advances in Therapy·Naris KitnarongAlexander R Kent
Dec 22, 2006·Expert Opinion on Drug Safety·Gábor Holló
Nov 6, 2008·Expert Opinion on Drug Safety·Esther Arranz-Marquez, Miguel A Teus
Mar 17, 2007·Current Eye Research·Ulrich ThelenWilliam C Stewart
Oct 22, 2008·Experimental Eye Research·Kathryn P B Cracknell, Ian Grierson
Jun 2, 2007·Clinical & Experimental Ophthalmology·Vignesh RajaBrendan Moriarty
Feb 22, 2012·Expert Opinion on Pharmacotherapy·Maurizio DigiuniLuca Rossetti
Feb 9, 2016·Expert Opinion on Emerging Drugs·Jed Asher Lusthaus, Ivan Goldberg
Aug 17, 2018·Journal of Glaucoma·Johan AspbergBoel Bengtsson
Aug 28, 2007·British Journal of Pharmacology·D F WoodwardA H-P Krauss
Jan 16, 2010·Journal of Glaucoma·Andrea CagigrigoriuFederico Maria Grignolo
Apr 11, 2006·Japanese Journal of Ophthalmology·UNKNOWN Latanoprost-Induced Iris Pigmentation Study Group
Mar 8, 2019·Cutaneous and Ocular Toxicology·Emine SenUfuk Elgin
Jan 4, 2013·Acta Ophthalmologica. Supplement·Anders HeijlUNKNOWN Swedish Ophthalmological Society
Jan 26, 2017·The Cochrane Database of Systematic Reviews·Dayse F Sena, Kristina Lindsley
Feb 27, 2015·Ophthalmic Plastic and Reconstructive Surgery·Philip L Custer, Tiffany L Kent
Mar 14, 2013·European Journal of Ophthalmology·Ingeborg StalmansAlain Bron
Sep 1, 2018·Vestnik oftalmologii·V P Erichev, V S Zinina
May 6, 2020·Vestnik oftalmologii·N I Kurysheva
Aug 19, 2016·Journal of Current Glaucoma Practice·Meenakshi WadhwaniTanuj Dada

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.